Online Event Location map
Peptides in Alzheimer's Research
Alzheimer‘s disease has become a major health and social problem in the developed countries with an increasing proportion of older people. Individuals suffering from this disease show a gradual loss of cognitive functions and disturbances in behavior. The onset of Alzheimer‘s disease is usually above 60 years and the risk to develop the disease increases with age.
In this webinar we present our amyloid peptides, inhibitors and labelled secretase substrates that are widely used in the research of Alzheimer’s disease. The deposition of amyloid β-peptide (Aβ) in the brain is characteristic for the disease and the resulting plaques mainly consist of Aβ (1-40) and Aβ (1-42). Despite of progresses in the understanding of the pathology of Alzheimer‘s disease, therapeutic strategies still rely on detailed knowledge of the molecules involved. Research covers the enzymatic processing of the amyloid precursor protein as well as the fate of the cleavage products.
Important enzymes include α, β- and γ-secretases, which cleave the amyloid precursor protein and define the composition of the resulting physiological peptides. Cleavage by β- and γ-secretases generates amyloid β-peptides. Inhibiting those enzymes has been suggested as a specific therapeutic intervention in preventing the progression of Alzheimer‘s disease. Cleavage products like amyloid β-peptides are e.g. used for in vitro aggregations studies.
There may be many networking opportunities at the Peptides in Alzheimer's Research. Find out more in the event details below.
Heads/Directors of Research & Development
Heads/Directors of Peptide Discovery & Chemistry
Exhibitor Information +